down arrow

Windtree Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US97382D4025
USD
0.06
0.01 (20.0%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.050.06

52 Week

0.0421.00
Valuation
Technical
Day's Volume

CASH

289.27 k

Shareholding (Mar 2025)

FII

0.06%

Held by 4 FIIs

DII

99.46%

Held by 0 DIIs

Promoter

0.10%

How big is Windtree Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Windtree Therapeutics, Inc. has a market capitalization of 2.19 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -16.04 million over the latest four quarters. The company's shareholder's funds are 13.18 million, and total assets are 27.88 million as of Dec 24.

Market Cap: As of Jun 18, Windtree Therapeutics, Inc. has a market capitalization of 2.19 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Windtree Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -16.04 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 13.18 million, while total assets were reported at 27.88 million.

Read More

What does Windtree Therapeutics, Inc. do?

22-Jun-2025

Windtree Therapeutics, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases, classified as a micro-cap with a market cap of $2.19 million and a recent net profit loss of $4 million. The company has no debt and does not pay dividends.

Overview: <BR>Windtree Therapeutics, Inc. is a biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2.19 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: -224.59% <BR>Price to Book: 0.19<BR><BR>Contact Details: <BR>Address: 2600 Kelly Rd Ste 100, WARRINGTON PA: 18976-3652 <BR>Tel: 1 215 4889300 <BR>Fax: 1 215 4889301 <BR>Website: http://www.windtreetx.com/

Read More

Who are in the management team of Windtree Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Windtree Therapeutics, Inc.'s management team includes Mr. James Huang (Independent Chairman), Mr. Craig Fraser (President and CEO), and Dr. Pratap Paruchuru (Executive Director of Clinical Development), along with several independent directors on the Board.

As of March 2022, the management team of Windtree Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. James Huang: Independent Chairman of the Board<BR>- Mr. Craig Fraser: President, Chief Executive Officer, Director<BR>- Dr. Pratap Paruchuru: Executive Director of Clinical Development<BR><BR>Additionally, the Board of Directors features several independent directors, including Mr. Daniel Geffken, Mr. John Leone, Mr. Joseph Mahady, Mr. Bruce Peacock, and Dr. Brian Schreiber.

Read More

Is Windtree Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of August 16, 2019, Windtree Therapeutics, Inc. is considered overvalued due to poor financial ratios, including a Price to Book Value of 0.18 and negative returns on capital and equity, indicating significant inefficiencies compared to its peers.

As of 16 August 2019, the valuation grade for Windtree Therapeutics, Inc. moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its financial ratios, including a Price to Book Value of 0.18 and an EV to Capital Employed of 0.19, both of which suggest poor asset utilization and financial performance. Additionally, the company has a negative ROCE of -217.14% and ROE of -224.59%, highlighting severe inefficiencies in generating returns for shareholders.<BR><BR>In comparison to its peers, Windtree Therapeutics, Inc. has an EV to EBITDA of -0.09, which is less favorable than Aileron Therapeutics, Inc. at -1.6430 and Soligenix, Inc. at -0.5878. This further reinforces the notion that Windtree is not only struggling in its operational metrics but also underperforming relative to similar companies in the sector. Overall, the combination of poor financial ratios and a lack of positive returns suggests that Windtree Therapeutics, Inc. is overvalued in the current market context.

Read More

Is Windtree Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Windtree Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish daily moving averages and underperformance of -99.56% year-to-date compared to the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for Windtree Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators include a bearish signal from the daily moving averages, while the weekly and monthly MACD are mildly bullish, indicating some divergence. The weekly RSI is bearish, and both the KST and Dow Theory are bearish across the weekly and monthly time frames. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.56% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.17

stock-summary
Return on Equity

-258.61%

stock-summary
Price to Book

0.32

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.46%
0%
-27.46%
6 Months
-93.01%
0%
-93.01%
1 Year
-99.8%
0%
-99.8%
2 Years
-99.99%
0%
-99.99%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Windtree Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Windtree Therapeutics, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Windtree Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators include a bearish signal from the daily moving averages, while the weekly and monthly MACD are mildly bullish, indicating some divergence. The weekly RSI is bearish, and both the KST and Dow Theory are bearish across the weekly and monthly time frames. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.56% versus the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
6.13%
EBIT to Interest (avg)
-19.06
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
1.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.77%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.18
EV to EBIT
-0.09
EV to EBITDA
-0.09
EV to Capital Employed
0.19
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-217.14%
ROE (Latest)
-224.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
Bullish
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.38%)

Foreign Institutions

Held by 4 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 11.67% vs -81.82% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-11.40",
          "chgp": "64.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.60",
          "val2": "-12.00",
          "chgp": "11.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 91.13% vs 48.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.90",
          "val2": "-17.50",
          "chgp": "-42.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "23.80",
          "val2": "-3.10",
          "chgp": "867.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-20.30",
          "chgp": "91.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.00
-11.40
64.91%
Interest
0.10
0.10
Exceptional Items
-6.30
0.00
Consolidate Net Profit
-10.60
-12.00
11.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 11.67% vs -81.82% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-24.90
-17.50
-42.29%
Interest
0.20
0.10
100.00%
Exceptional Items
23.80
-3.10
867.74%
Consolidate Net Profit
-1.80
-20.30
91.13%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 91.13% vs 48.21% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Windtree Therapeutics, Inc. stock-summary
stock-summary
Windtree Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Company Coordinates stock-summary
Company Details
2600 Kelly Rd Ste 100 , WARRINGTON PA : 18976-3652
stock-summary
Tel: 1 215 4889300
stock-summary
http://www.windtreetx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."